Immatics Biotechnologies Valuation
| IMTXW Stock | USD 0.41 0.01 2.38% |
Immatics Biotechnologies is overvalued. Immatics Biotechnologies retains a regular Real Value of $0.38 per share. The prevalent price of the firm is $0.41. Our model calculates the value of Immatics Biotechnologies from evaluating the firm fundamentals such as Number Of Shares Shorted of 736, return on equity of -0.24, and Return On Asset of -0.12 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Immatics Biotechnologies' price fluctuation is out of control at this time. Calculation of the real value of Immatics Biotechnologies is based on 3 months time horizon. Increasing Immatics Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Immatics stock is determined by what a typical buyer is willing to pay for full or partial control of immatics biotechnologies GmbH. Since Immatics Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immatics Stock. However, Immatics Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.41 | Real 0.38 | Hype 0.26 |
The intrinsic value of Immatics Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immatics Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of immatics biotechnologies GmbH helps investors to forecast how Immatics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immatics Biotechnologies more accurately as focusing exclusively on Immatics Biotechnologies' fundamentals will not take into account other important factors: Immatics Biotechnologies Total Value Analysis
immatics biotechnologies GmbH is currently anticipated to have takeover price of 0 with market capitalization of 673 M, debt of 15.4 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Immatics Biotechnologies fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 673 M | 15.4 M |
Immatics Biotechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immatics Biotechnologies has an asset utilization ratio of 10.59 percent. This indicates that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that immatics biotechnologies GmbH is more efficient with each dollar of assets it utilizes for everyday operations.Immatics Biotechnologies Profitability Analysis
The company reported the revenue of 54 M. Net Loss for the year was (96.99 M) with profit before overhead, payroll, taxes, and interest of 0.About Immatics Biotechnologies Valuation
Our relative valuation model uses a comparative analysis of Immatics Biotechnologies. We calculate exposure to Immatics Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immatics Biotechnologies's related companies.Immatics Biotechnologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Immatics Biotechnologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 80.5 M |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.